Physician profile
Amy E Dempsey
NPI 1689864266
$2,823.15
in general payments reported to CMS, 2019-2025
32 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $481 · 2022: $772 · 2023: $734 · 2024: $378 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.68 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $463.89 | 2021-2025 | |
| Avion Pharmaceuticals | $254.55 | 2021-2023 | Balcoltra |
| Teva Pharmaceuticals USA, INC. | $239.90 | 2022-2023 | Austedo, Austedo Xr |
| Astellas Pharma US INC | $188.25 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $151.80 | 2021-2025 | Nexplanon |
| Abbvie INC. | $146.33 | 2022-2023 | |
| Novo Nordisk INC | $144.71 | 2022-2025 | Wegovy |
| Pfizer INC. | $128.23 | 2021-2023 | |
| Agile Therapeutics, INC. | $121.48 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $113.58 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $112.04 | 2021-2022 | |
| Hologic Sales and Service, LLC | $92.90 | 2023-2024 | Acessa Provu System |
| Aspira Women'S Health INC | $72.86 | 2022 | |
| Alkermes, INC. | $72.58 | 2024 | Aristada, Lybalvi |
| Evofem Biosciences, INC. | $64.49 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.89 | 2025 | The Cologuard Plus Collection Kit |
| Ascend Therapeutics US, LLC | $42.72 | 2022 | |
| Millicent US INC | $37.66 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Amgen INC. | $35.15 | 2024-2025 | Evenity, Prolia, Prolia |
| Cumberland Pharmaceuticals, INC. | $31.26 | 2021 | |
| Sumitomo Pharma America, INC. | $26.98 | 2025 | Myfembree |
| Coopersurgical, INC. | $25.00 | 2025 | Paragard T 380a |
| Vertex Pharmaceuticals Incorporated | $23.20 | 2025 | |
| Ucb, INC. | $22.71 | 2024 | Rystiggo |
| Kerecis Limited | $22.01 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Bayer Healthcare Pharmaceuticals INC. | $21.62 | 2022 | |
| Mylan Pharmaceuticals INC. | $21.62 | 2022 | |
| Medicem INC. | $19.25 | 2021 | |
| Scynexis, INC. | $17.54 | 2022 | |
| Convatec INC. | $16.38 | 2022 | |
| Vital Connect, INC | $15.97 | 2025 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $15.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.